NEW
YORK, July 4, 2024 /PRNewswire/ -- The
global autism spectrum disorder therapeutics market size is
estimated to grow by USD 766.1
million from 2024-2028, according to Technavio. The market
is estimated to grow at a CAGR of 6.78% during the forecast
period. Increasing prevalence of asd is driving market
growth, with a trend towards increasing interest in
personalized medicine for treatment of ASD. However, stringent
regulations on asd therapeutics and treatments poses a challenge.
Key market players include ASSERTIO HOLDINGS INC., AutismSTEP,
Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd.,
Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services
Inc., Les Laboratoires Servier, Neurim Pharmaceuticals Ltd.,
Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd.,
PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Stalicla
SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, and
Zynerba Pharmaceuticals Inc..
![Technavio has announced its latest market research report titled Global autism spectrum disorder therapeutics market 2024-2028 Technavio has announced its latest market research report titled Global autism spectrum disorder therapeutics market 2024-2028](https://mma.prnewswire.com/media/2453594/Technavio__announced_its_latest_market_research_report_titled_Global_autism_spectrum_disorder_the.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Distribution Channel
(Retail pharmacy, Hospital pharmacy, and Online pharmacy), Type
(Stimulants, Selective serotonin reuptake inhibitors, Antipsychotic
drugs, Sleep medications, and Others), and Geography (North
America, Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
ASSERTIO HOLDINGS INC.,
AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La
Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson
Services Inc., Les Laboratoires Servier, Neurim Pharmaceuticals
Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd.,
PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Stalicla
SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, and
Zynerba Pharmaceuticals Inc.
|
Key Market Trends Fueling Growth
Personalized medicine, which involves customized treatments
based on individual patients' genetic, environmental, and lifestyle
factors, is gaining traction in the autism spectrum disorder (ASD)
therapeutics market. The complexity and diversity of ASD symptoms
and severity make it challenging to develop effective medications
for all individuals. Genetic testing plays a crucial role in
personalized medicine for ASD. Researchers are investigating
genetic variants contributing to ASD and creating targeted
treatments. For instance, mutations in the SHANK3 gene are linked
to severe ASD forms, and new treatments are being explored to
target this gene. Additionally, researchers are examining
biomarkers to identify specific ASD subtypes and develop customized
treatments. Brain imaging, gene expression, and metabolic
indicators are among the biomarkers under investigation. This
increasing focus on personalized medicine for ASD is a significant
trend fueling the growth of the global autism spectrum disorder
therapeutics market.
The Autism Spectrum Disorder (ASD) Therapeutics Market is
experiencing significant growth due to increased awareness and
early diagnosis. Antipsychotic drugs, primarily used for aggressive
behaviors and mood stabilization, dominate the market. Hospital
Pharmacies and Drug Stores are key distributors. Personalized and
innovative therapies, including behavioral and novel ones, are
emerging trends. Pediatric and adult patients require different
approaches, considering heterogeneity and symptom severity.
Underlying mechanisms and genetic insights guide drug development
and approvals. Geographic presence and personalized medicine are
driving the market forward. Biotechnology companies focus on novel
therapies, including targeted ones, for ASDs like Autistic Disorder
and Asperger's Syndrome. Remote monitoring and brain-focused
treatments are also gaining traction. The market caters to
neurological disorders, social interaction challenges, and the
diverse needs of children, adults, and various
ethnicities.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The Autism Spectrum Disorder (ASD) therapeutics market is
subject to rigorous regulatory oversight from agencies like the US
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA), ensuring the safety and efficacy of treatments.
Antipsychotics, used to manage certain ASD symptoms, have potential
side effects, such as weight gain and mobility issues. This ongoing
debate about their use necessitates clear guidelines. The diverse
symptoms and severity of ASD complicate regulatory approval
processes and create uncertainty among healthcare providers
regarding optimal treatment methods. Strict regulations on ASD
therapeutics may hinder market growth during the forecast
period.
- The Autism Spectrum Disorder (ASD) therapeutics market faces
significant challenges due to behavioral symptoms, anxiety, and
depressive symptoms in children. The heterogeneity and symptom
severity of ASD make drug development complex. Understanding the
underlying mechanisms of ASD is crucial for creating effective
therapies. With a prevalence rate of approximately 1 in 54
children, early diagnosis is essential. However, the age of
diagnosis varies, and ethnicity plays a role. Biotechnology
companies are developing personalized medicine and targeted
therapies based on genetic insights. Drug approvals are limited,
with only a few medications available. Geographic presence and
remote monitoring technologies expand access to care. Novel
therapies, including those targeting the brain, show promise. ASD
is a genetic condition affecting social interaction and
communication in individuals with autistic disorder and Asperger's
syndrome. The birth rate of children with ASD continues to rise,
making it a critical area for neurological disorder research and
medication in hospitals.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This autism spectrum disorder therapeutics market report
extensively covers market segmentation by
- Distribution Channel
- 1.1 Retail pharmacy
- 1.2 Hospital pharmacy
- 1.3 Online pharmacy
- Type
- 2.1 Stimulants
- 2.2 Selective serotonin reuptake inhibitors
- 2.3 Antipsychotic drugs
- 2.4 Sleep medications
- 2.5 Others
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Retail pharmacy- The Autism Spectrum Disorder (ASD)
therapeutics market is projected to expand significantly due to the
rising prevalence of ASD and increasing awareness of the condition.
Retail pharmacies serve as a crucial access point for patients,
offering a range of medications and therapies. These include
prescription drugs like antipsychotics, antidepressants, and
stimulants, as well as over-the-counter (OTC) supplements and
vitamins. As new treatment options emerge, retail pharmacies will
remain essential in providing convenient access to these solutions
for individuals with ASD. The growing demand for effective
therapeutics, fueled by heightened awareness and a larger patient
population, will drive market expansion. Retail pharmacies' role in
making these treatments available is expected to be pivotal in the
forecast period.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Research Analysis
The Autism Spectrum Disorder (ASD) Therapeutics Market
encompasses various treatments for individuals diagnosed with
autism, including antipsychotic drugs. These medications are
primarily used to manage aggressive behaviors, mood stabilization,
and symptoms related to sensory overload. Hospital Pharmacies and
Drug Stores are significant distribution channels for these
therapies. Awareness and early diagnosis are crucial for effective
treatment, with the prevalence of ASD estimated to affect
approximately 1 in 54 children and 1 in 44 boys. Personalized and
innovative therapies, including behavioral interventions, are
increasingly being explored to cater to the diverse needs of
pediatric and adult patients with ASD, which is a genetic condition
affecting the brain and characterized by disorders in social
interaction, communication, and repetitive behaviors, including
Autistic Disorder and Asperger's Syndrome. The diagnosis rate
continues to rise, with children often diagnosed between the ages
of 2 and 5.
Market Research Overview
The Autism Spectrum Disorder (ASD) Therapeutics Market
encompasses various interventions, including medications and
behavioral therapies, to manage the diverse symptoms of this
complex neurodevelopmental disorder. Antipsychotic drugs are
commonly used to address aggressive behaviors, mood stabilization,
and anxiety in ASD patients. Hospital Pharmacies and Drug Stores
play crucial roles in dispensing these medications. Rising
awareness and early diagnosis, driven by increased public education
and advancements in genetic insights, fuel market growth.
Personalized therapies and innovative treatments, such as targeted
therapies and novel brain-based interventions, are gaining
prominence. Pediatric and adult patients with ASD exhibit
heterogeneity in symptom severity and underlying mechanisms,
necessitating a range of therapeutic approaches. Drug development
and approvals continue to expand the market's geographic presence.
The ASD therapeutics landscape includes medications, behavioral
therapies, and emerging technologies like remote monitoring and
genetic-informed treatments. Neurological disorders, including
Autistic Disorder and Asperger's Syndrome, affect social
interaction and communication, with prevalence rates varying by
age, ethnicity, and birth rate. Biotechnology companies are at the
forefront of developing new medications and therapies to address
the unique needs of ASD patients.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Distribution Channel
-
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Type
-
- Stimulants
- Selective Serotonin Reuptake Inhibitors
- Antipsychotic Drugs
- Sleep Medications
- Others
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/autism-spectrum-disorder-therapeutics-market-size-is-set-to-grow-by-usd-766-1-million-from-2024-2028--increasing-prevalence-of-asd-to-boost-the-market-growth-technavio-302188939.html
SOURCE Technavio